{"prompt": "['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', '7.', 'BIOLOGICAL SAMPLING PROCEDURES', '7.1', 'Volume of blood', 'Table 2 provides an approximation of the amount of blood that will be drawn for the safety', 'and biomarker assessments outlined in Sections 5.2 and 5.3. In general, these labs will not all', 'be drawn at the same visit, and this table provides an estimate for the upper limit of blood', 'volume required from a patient at any given visit. The number of samples taken, as well as the', 'volume required for each analysis, may be changed during the study as new data on the study', 'treatment becomes available.', 'The total volume of blood that will be drawn from each subject in this study is as follows:', 'Table 2. Volume of Blood to Be Drawn From Each Subject', 'Assessment', 'Sample', 'No. of', 'Total', 'volume', 'samples', 'volume', '(mL)', '(mL)', 'Safety\u00b9', 'Clinical chemistry', '5', '1', '5', 'Hematology', '3', '1', '3', 'Coagulation', '3', '1', '3', 'Hepatitis panel', '5', '1', '5', 'Exploratory biomarker', 'CTC studies', '10', '2', '20', 'research', 'ctDNA studies', '10', '1', '10', 'Serum hormone', '10', '1', '10', 'levels', 'Total', '46', '8', '56', '1.', 'The sample volumes for safety assessments are approximate volumes that are subject to change.', 'Additional blood samples may be needed depending on the results of these studies and if patients', 'require follow up testing or undergo additional procedures (e.g. fresh metastatic biopsy).', '7.2', 'Handling, storage and destruction of biological samples', 'Biospecimen samples will be stored for up to five years following the completion of this', 'study. Samples will be stored at University of Washington and/or Fred Hutchinson Cancer', 'Research Center (UW/FHCRC). These samples may also be sent to our research partners', 'participating in this study, including AstraZeneca. Specimens will not be used for reasons', 'unrelated to this research study. All specimens will be kept in locked research laboratories at', 'UW/FHCRC. The use of these specimens will be supervised by the Principal Investigator', '(Michael Schweizer, MD) and his designees.', '57(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', '8.', 'STUDY CONDUCT', '8.1', 'Restrictions during the study', '8.1.1', 'Grapefruit juice', 'It is prohibited to consume grapefruit juice while on olaparib therapy.', '8.1.2', 'Contraception', 'Patients with partners of child bearing potential, who are sexually active, must agree to the use', 'of two highly effective forms of contraception. This should be started from the signing of the', 'informed consent and continue throughout period of taking study medication and for 3 months', 'after last dose of study drug. Male patients should not donate sperm throughout the period of', 'taking olaparib and for 3 months following the last dose of olaparib.', 'For details refer to Appendix 3 Acceptable Birth Control Methods.', '8.2', 'Treatments', '8.2.1', 'Identity of investigational product(s)', 'The AstraZeneca Pharmaceutical Development R&D Supply Chain will supply olaparib to the', 'investigator as round or oval green film coated tablets', 'Investigational product', 'Dosage form and strength', 'Olaparib', '100 mg tablet', 'Olaparib', '150 mg tablet', 'a', \"Descriptive information for olaparib can be found in the Investigator's Brochure\", '8.2.2', 'Olaparib doses and treatment regimens', 'Olaparib will be packed in high-density polyethylene (HDPE) bottles with child-resistant', 'closures. Each dosing container will contain sufficient medication for at least 28 days plus', 'overage. Olaparib will be dispensed to patients on Day 1 and every 28 days thereafter until', 'the patient completes the study, withdraws from the study or closure of the study.', 'Study treatment is available as tablets containing 50mg of olaparib.', 'Patients will be administered olaparib twice daily at 300 mgs bid continually. 300 mg olaparib', 'should be taken at the same time each day, approximately 12 hours apart with one glass of', 'water. The olaparib tablets should be swallowed whole and not chewed, crushed, dissolved or', 'divided. Olaparib tablets can be taken with or without food.', '58(93)', 'Printed on 3/25/202']\n\n###\n\n", "completion": "END"}